^
    Back
    Association details:
    Biomarker:BRCA2 mutation
    Cancer:Triple Negative Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Exp Clin Cancer Res
    Title:

    Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

    Published date:
    04/08/2021
    Excerpt:
    We demonstrated for the first time that the combination of olaparib and palbociclib has synergistic effects against BRCAmut/TNBC both in vitro and in vivo...the combination of olaparib and palbociclib greatly inhibited HR during the G2 phase, increased DNA damage and inhibited tumour growth.
    DOI:
    10.1186/s13046-021-01930-w